Physician profile
Deatte Gettinger
NPI 1891179917
$2,278.72
in general payments reported to CMS, 2019-2025
22 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $573 · 2022: $409 · 2023: $36.83 · 2024: $762 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238 · Education: $59.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.49 |
| Education | $59.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $619.34 | 2023-2025 | Caplyta |
| Abbvie INC. | $547.38 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.84 | 2021-2022 | |
| Abbott Laboratories | $171.66 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $116.04 | 2021-2022 | |
| Lilly USA, LLC | $80.72 | 2021-2022 | |
| Novo Nordisk INC | $74.45 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $62.95 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Sanofi-Aventis U.S. LLC | $55.16 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $43.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $42.16 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $35.91 | 2024 | Uzedy, Austedo Xr |
| Alkermes, INC. | $30.02 | 2021-2025 | Aristada, Lybalvi |
| Biohaven Pharmaceuticals, INC. | $27.53 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.13 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $25.27 | 2021 | |
| Lundbeck LLC | $18.49 | 2025 | Rexulti |
| Indivior INC. | $16.08 | 2024 | Sublocade |
| Pfizer INC. | $14.75 | 2021 | |
| Amarin Pharma, INC. | $14.28 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.22 | 2021 | |
| Eisai INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deatte Gettinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.